All News
Does Exercise and Lifestyle Modification Improve RA?
Does exercise or lifestyle modifications reduce the risk of getting rheumatoid arthritis (RA) or change those with early RA?
ABA versus HCQ in Palindromic Rheumatism
Palindromic rheumatism may develop rheumatoid arthritis (RA) and could be an at-risk population. A pilot trial compared abatacept (ABA) versus hydroxychloroquine and demonstrated ABA reduces RA development in a 2 year study.
Read Article
Update on Multicentric Reticulohistiocytosis
Have you ever seen multicentric reticulohistiocytosis? Don't worry, it's a rare non-Langerhans cell histiocytosis condition, characterized by papulonodular skin lesions and symmetric erosive polyarthritis, and has only been described in fewer than 500 cases reported worldwide.
Read Article
Infectious Rheumatology (5.15.2026)
Dr. Jack Cush discusses his favorite journal articles from the past week on RheumNow.com.
Read Article
FDA has approved benralizumab (Fasenra) for the treatment of adult and pediatric patients w/ hypereosinophilic syndrome (HES); based on the NATRON Phase III trial https://t.co/qqPsjhUClP https://t.co/lCZNoTh9fv
Dr. John Cush RheumNow ( View Tweet)
ANCA-Assoc. Vasculitis has great Rx optionis, BUT still no reliable biomaker to predict relapse or renal outcomes, this includes IL-6. But there is hope for CD163 in the future. https://t.co/lFyfTPj5vG https://t.co/wLfOPz76JC
Dr. John Cush RheumNow ( View Tweet)
10yr retrosp. study of 110 Still’s dz pts. MAS occurred in 37% (1/2 @onset; assoc w/ serositis) and ILD observed in 82% (also assoc w/ MAS, polycyclic course) https://t.co/SNa0KiWfgY https://t.co/xbpCuHdJka
Dr. John Cush RheumNow ( View Tweet)
Another IL-17A inhibitor (Vunakizumab) for active Ankylosing Spondylitis
Vunakizumab, a novel anti–interleukin (IL) 17A monoclonal antibody, was studied in patients with active radiographic axial spondyloarthritis [r-axSpA] and found to be effective and tolerable. https://t.co/y0mw7tRWbs
Dr. John Cush RheumNow ( View Tweet)
Fatigue in SLE
An NIH lupus cohort study looked at fatigue in SLE and found associations with organ damage, obesity, but does not correlate with disease activity in systemic lupus erythematosus (SLE) patients.
https://t.co/JEAnhMFJD8 https://t.co/sROKzsyISl
Links:
Dr. John Cush RheumNow ( View Tweet)
"Everything will be alright in the end; and if its not alright, then its not yet the end"
– Suni Kapoor Best exotic Marigold Hotel https://t.co/Yua7t4yoZe
Dr. John Cush RheumNow ( View Tweet)
Registry of 587 #SLE pts. 30% were RNP+ --> more dz activity than RNP- (SLEDAI-2 8.0 vs 4.0) and more Rx use (daily GC 6.8 vs 3 mg). RNP+ more renal, skin & serologic activity & less likely to LLDAS (20% vs 32%) or REM (12% vs 23%). RNP + 18-fold more likely to be Sm+ https://t.co/9i3BBGA0uu
Dr. John Cush RheumNow ( View Tweet)
Vitamin D in Rheumatic Disease - Is It Good Enough?
Vitamin D in rheumatic disease — is it sufficient? Vitamin D deficiency/insufficiency is common and linked to inflammatory rheumatic diseases, raising the question of whether low vitamin D drives immune dysregulation, disease https://t.co/Xd8s8LKqKT
Dr. John Cush RheumNow ( View Tweet)
Parvovirus B19 Infection - Images from JAMA Dermatology. 40yoM 2-days asymptomatic rash w/ fever to 39°C, w/ arthralgias, Rash on BL cheeks, inguinal, flanks, axilla. WBC =2K, CRP 1.24 mg/dl. Dx by PCR for parvovirus B19 DNA https://t.co/LGGnabvFvA https://t.co/XzPlaWkIfz
Links:
Dr. John Cush RheumNow ( View Tweet)
Meet the RheumNow #EULAR2026 Reporting Team
Delivering real-time insights from the forefront of rheumatology:
🩺 Dr. Antoni Chan (@synovialjoints)
🩺 Dr. Mrinalini Dey (@DrMiniDey)
🩺 Dr. Jiha Lee (@JihaRheum)
🩺 Dr. Aurelie Najm (@AurelieRheumo)
🩺 Dr. Janet Pope https://t.co/zpIeGWpL6P
Dr. John Cush RheumNow ( View Tweet)
Toll-Like Receptor Drugs Effective in Cutaneous Lupus
Enpatoran, an investigational oral drug that inhibits Toll-like receptors (TLR) 7 and 8, was superior to placebo in relieving lupus skin manifestations in a dose-finding phase II trial.
https://t.co/R1wbJHXwjD https://t.co/65HtG0Te94
Dr. John Cush RheumNow ( View Tweet)
Lupus Mortality Risk in Young Women
New research using death certificate data from 52,942 females, reveals that systemic lupus erythematosus (lupus) is a leading cause of years of potential life lost among young women in the United States, underscoring the disease’s significant https://t.co/2FSINr6gZN
Dr. John Cush RheumNow ( View Tweet)
Branebrutinib (Bruton's tyrosine kinase inhibitor) was studied in phase 2 RCT of 85 RA pts for 12 weeks and was safe but failed to achieve an ACR50 response (19% BTK vs 33% PBO; p=0·16). https://t.co/gTjLJm9iIW https://t.co/GN9p1P8ZNJ
Dr. John Cush RheumNow ( View Tweet)
RA adds to mortality risk in nontuberculous mycobact. infx (NTM). Retro study 1420 NTM pts, 66 (4.6) had RA. RA was independent predictor of resp-death (HR 4.30) - partly explained by ILD & systemic inflammation https://t.co/S9bndHsXCE https://t.co/mC74Qve1LZ
Dr. John Cush RheumNow ( View Tweet)
NEJM reports a 10 yrs study of Arthroscopic Partial Meniscectomy (APM) for Degenerative Tear — randomized, sham-surgery–controlled RCT of 147 pts w/o Knee https://t.co/WMGRIOunwZ 10 years, found no signif benefit betw APM and Sham surgery (pain, function) & possible worsening https://t.co/979C7IYuyZ
Dr. John Cush RheumNow ( View Tweet)
UCB has aquired Candid Therapeutics for $2 billion; plan to lead in autoimmune dz by acquiring cizutamig - a T cell engager. Its been studied in >100 pts, including early Global Phase 2 RCTs of myasthenia gravis & ILD. https://t.co/xz4uEhvxu6 https://t.co/6FS1riLecW
Dr. John Cush RheumNow ( View Tweet)
